Splenogonadal fusion has also been identified in infants with Möbius syndrome and Poland syndrome. Diagnosis
Diagnosis can be challenging pre-operatively, as patients are commonly asymptomatic. Physical examination can aid in diagnosis if the mass is palpated, but further confirmatory tests are necessary. Females are reportedly less affected by splenogonadal fusion, though it is possible that the condition is underdiagnosed due to the difficulty of internal gonad examination in females. On scrotal ultrasound, ectopic splenic tissue may appear as an encapsulated homogeneous extratesticular mass, isoechoic with the normal testis. Subtle hypoechoic nodules may be present in the mass. Limitations of doppler ultrasonography include visualizing the nonspecific paratesticular masses which can mimic malignancies such as rhabdomyosarcoma or embryonal sarcoma. Technetium-99m sulfur colloid scan is sensitive to target the liver, spleen, and bone marrow, therefore the scans can be used to identify ectopic splenic tissue when clinical suspicion is high. When technetium-99m sulfur colloid scans are not included in a patients diagnostic workup, the diagnosis is often not made until the surgeon performs an abdominal exploration using laparoscopy which can visualize the splenic tissue grossly. Evaluation by biopsy including frozen section procedure is confirmatory for splenogonadal fusion. Histological examination will show normal splenic tissue which is made up of red and white pulp. Many people with splenogonadal fusion go undiagnosed without complication during their lifetime. Many cases have been diagnosed at autopsy or incidentally after orchiectomy. Treatment
Treatment remains controversial given the benign nature of splenogonadal fusion. Splenogonadal fusion does not have known clinical manifestations that require intervention.
Oxycodone/paracetamol, sold under the brand name Percocet among others, is a combination of the opioid oxycodone with paracetamol (acetaminophen), used to treat moderate to severe pain. In 2019, it was the 59th most commonly prescribed medication in the United States, with more than 11 million prescriptions. History
The United States Food and Drug Administration (FDA) first approved Percocet in 1976, under application ANDA 085106. Implicated in deaths
On June 30, 2009, an FDA advisory panel recommended that Percocet, Vicodin, and every other combination of acetaminophen with narcotic analgesics be limited in their sales because of their contributions to an alleged 400 acetaminophen-related deaths in the U.S. each year, that were attributed to acetaminophen overdose and associated liver damage.In December 2009, the Canadian Medical Association Journal reported a study finding a fivefold increase in oxycodone-related deaths in Ontario (mostly accidental) between 1991 and 2007 that led to a doubling of all opioid-related deaths in Ontario over the same period.In March 2017, U.S. President Donald Trump initiated the Opioid and Drug Abuse Commission. In July 2017, an interim report was published. Some excerpts:

References
External links
"Acetaminophen mixture with Oxycodone". Drug Information Portal. U.S. National Library of Medicine. "Prescription Acetaminophen Products to be Limited to 325 mg Per Dosage Unit; Boxed Warning Will Highlight Potential for Severe Liver Failure". U.S. Food and Drug Administration. 13 January 2011. "FDA warns about several safety issues with opioid pain medicines; requires label changes". U.S. Food and Drug Administration. 22 March 2016.